In the RV144 trial, HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with the decreased risk of HIV-1 infection [62]. Here, IGHG3 is linked to HIV-1 infection.